Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia

Clement C. Zai; Arun K. Tiwari; Nabilah I. Chowdhury; Zeynep Yilmaz; Vincenzo de Luca; Daniel J. Müller; Steven G. Potkin; Jeffrey A. Lieberman; Herbert Y. Meltzer; Aristotle N. Voineskos; Gary Remington; James L. Kennedy

doi:10.1080/15622975.2017.1301681

Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia

Clement C. Zai^*, Arun K. Tiwari, Nabilah I. Chowdhury, Zeynep Yilmaz, Vincenzo de Luca, Daniel J. Müller, Steven G. Potkin, Jeffrey A. Lieberman, Herbert Y. Meltzer, Aristotle N. Voineskos, Gary Remington, James L. Kennedy

^*Corresponding author for this work

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article

5 Scopus citations

Abstract

Objectives: Tardive dyskinesia (TD) is a movement disorder that may develop as a side effect of antipsychotic medication. The aetiology underlying TD is unclear, but a number of mechanisms have been proposed. Methods: We investigated single-nucleotide polymorphisms (SNPs) in the genes coding for neuregulin-1 and erbB-4 receptor in our sample of 153 European schizophrenia patients for possible association with TD. Results: We found the ERBB4 rs839523 CC genotype to be associated with risk for TD occurrence and increased severity as measured by the Abnormal Involuntary Movement Scale (AIMS) (P =.003). Conclusions: This study supports a role for the neuregulin signalling pathway in TD, although independent replications are warranted.

Original language	English (US)
Pages (from-to)	91-95
Number of pages	5
Journal	World Journal of Biological Psychiatry
Volume	20
Issue number	1
DOIs	https://doi.org/10.1080/15622975.2017.1301681
State	Published - Jan 2 2019

Fingerprint

Keywords

Tardive dyskinesia
neuregulin 1 (NRG1)
pharmacogenetics
receptor tyrosine-protein kinase erbB-4 (ERBB4)
schizophrenia

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Cite this

Zai, C. C., Tiwari, A. K., Chowdhury, N. I., Yilmaz, Z., de Luca, V., Müller, D. J., Potkin, S. G., Lieberman, J. A., Meltzer, H. Y., Voineskos, A. N., Remington, G., & Kennedy, J. L. (2019). Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. World Journal of Biological Psychiatry, 20(1), 91-95. https://doi.org/10.1080/15622975.2017.1301681

Zai, Clement C. ; Tiwari, Arun K. ; Chowdhury, Nabilah I. ; Yilmaz, Zeynep ; de Luca, Vincenzo ; Müller, Daniel J. ; Potkin, Steven G. ; Lieberman, Jeffrey A. ; Meltzer, Herbert Y. ; Voineskos, Aristotle N. ; Remington, Gary ; Kennedy, James L. / Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. In: World Journal of Biological Psychiatry. 2019 ; Vol. 20, No. 1. pp. 91-95.

@article{3aae1dca0eef4229a88ffbdf437e93bd,

title = "Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia",

abstract = "Objectives: Tardive dyskinesia (TD) is a movement disorder that may develop as a side effect of antipsychotic medication. The aetiology underlying TD is unclear, but a number of mechanisms have been proposed. Methods: We investigated single-nucleotide polymorphisms (SNPs) in the genes coding for neuregulin-1 and erbB-4 receptor in our sample of 153 European schizophrenia patients for possible association with TD. Results: We found the ERBB4 rs839523 CC genotype to be associated with risk for TD occurrence and increased severity as measured by the Abnormal Involuntary Movement Scale (AIMS) (P =.003). Conclusions: This study supports a role for the neuregulin signalling pathway in TD, although independent replications are warranted.",

keywords = "Tardive dyskinesia, neuregulin 1 (NRG1), pharmacogenetics, receptor tyrosine-protein kinase erbB-4 (ERBB4), schizophrenia",

author = "Zai, {Clement C.} and Tiwari, {Arun K.} and Chowdhury, {Nabilah I.} and Zeynep Yilmaz and {de Luca}, Vincenzo and M{\"u}ller, {Daniel J.} and Potkin, {Steven G.} and Lieberman, {Jeffrey A.} and Meltzer, {Herbert Y.} and Voineskos, {Aristotle N.} and Gary Remington and Kennedy, {James L.}",

year = "2019",

month = jan,

day = "2",

doi = "10.1080/15622975.2017.1301681",

language = "English (US)",

volume = "20",

pages = "91--95",

journal = "World Journal of Biological Psychiatry",

issn = "1562-2975",

publisher = "Informa Healthcare",

number = "1",

}

Zai, CC, Tiwari, AK, Chowdhury, NI, Yilmaz, Z, de Luca, V, Müller, DJ, Potkin, SG, Lieberman, JA, Meltzer, HY, Voineskos, AN, Remington, G & Kennedy, JL 2019, 'Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia', World Journal of Biological Psychiatry, vol. 20, no. 1, pp. 91-95. https://doi.org/10.1080/15622975.2017.1301681

Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. / Zai, Clement C.; Tiwari, Arun K.; Chowdhury, Nabilah I.; Yilmaz, Zeynep; de Luca, Vincenzo; Müller, Daniel J.; Potkin, Steven G.; Lieberman, Jeffrey A.; Meltzer, Herbert Y.; Voineskos, Aristotle N.; Remington, Gary; Kennedy, James L.

In: World Journal of Biological Psychiatry, Vol. 20, No. 1, 02.01.2019, p. 91-95.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia

AU - Zai, Clement C.

AU - Tiwari, Arun K.

AU - Chowdhury, Nabilah I.

AU - Yilmaz, Zeynep

AU - de Luca, Vincenzo

AU - Müller, Daniel J.

AU - Potkin, Steven G.

AU - Lieberman, Jeffrey A.

AU - Meltzer, Herbert Y.

AU - Voineskos, Aristotle N.

AU - Remington, Gary

AU - Kennedy, James L.

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Objectives: Tardive dyskinesia (TD) is a movement disorder that may develop as a side effect of antipsychotic medication. The aetiology underlying TD is unclear, but a number of mechanisms have been proposed. Methods: We investigated single-nucleotide polymorphisms (SNPs) in the genes coding for neuregulin-1 and erbB-4 receptor in our sample of 153 European schizophrenia patients for possible association with TD. Results: We found the ERBB4 rs839523 CC genotype to be associated with risk for TD occurrence and increased severity as measured by the Abnormal Involuntary Movement Scale (AIMS) (P =.003). Conclusions: This study supports a role for the neuregulin signalling pathway in TD, although independent replications are warranted.

AB - Objectives: Tardive dyskinesia (TD) is a movement disorder that may develop as a side effect of antipsychotic medication. The aetiology underlying TD is unclear, but a number of mechanisms have been proposed. Methods: We investigated single-nucleotide polymorphisms (SNPs) in the genes coding for neuregulin-1 and erbB-4 receptor in our sample of 153 European schizophrenia patients for possible association with TD. Results: We found the ERBB4 rs839523 CC genotype to be associated with risk for TD occurrence and increased severity as measured by the Abnormal Involuntary Movement Scale (AIMS) (P =.003). Conclusions: This study supports a role for the neuregulin signalling pathway in TD, although independent replications are warranted.

KW - Tardive dyskinesia

KW - neuregulin 1 (NRG1)

KW - pharmacogenetics

KW - receptor tyrosine-protein kinase erbB-4 (ERBB4)

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85017224338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017224338&partnerID=8YFLogxK

U2 - 10.1080/15622975.2017.1301681

DO - 10.1080/15622975.2017.1301681

M3 - Article

C2 - 28394697

AN - SCOPUS:85017224338

VL - 20

SP - 91

EP - 95

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

SN - 1562-2975

IS - 1

ER -

Access to Document

10.1080/15622975.2017.1301681